Literature DB >> 29177427

Synaptic phosphorylated α-synuclein in dementia with Lewy bodies.

Martí Colom-Cadena1,2, Jordi Pegueroles1,2, Abigail G Herrmann3, Christopher M Henstridge3, Laia Muñoz1,2, Marta Querol-Vilaseca1,2, Carla San Martín-Paniello1,2, Joan Luque-Cabecerans1,2, Jordi Clarimon1,2, Olivia Belbin1,2, Raúl Núñez-Llaves1,2, Rafael Blesa1,2, Colin Smith4, Chris-Anne McKenzie4, Matthew P Frosch5, Allyson Roe5, Juan Fortea1,2, Jordi Andilla6, Pablo Loza-Alvarez6, Ellen Gelpi7, Bradley T Hyman5, Tara L Spires-Jones3, Alberto Lleó1,2.   

Abstract

Dementia with Lewy bodies is characterized by the accumulation of Lewy bodies and Lewy neurites in the CNS, both of which are composed mainly of aggregated α-synuclein phosphorylated at Ser129. Although phosphorylated α-synuclein is believed to exert toxic effects at the synapse in dementia with Lewy bodies and other α-synucleinopathies, direct evidence for the precise synaptic localization has been difficult to achieve due to the lack of adequate optical microscopic resolution to study human synapses. In the present study we applied array tomography, a microscopy technique that combines ultrathin sectioning of tissue with immunofluorescence allowing precise identification of small structures, to quantitatively investigate the synaptic phosphorylated α-synuclein pathology in dementia with Lewy bodies. We performed array tomography on human brain samples from five patients with dementia with Lewy bodies, five patients with Alzheimer's disease and five healthy control subjects to analyse the presence of phosphorylated α-synuclein immunoreactivity at the synapse and their relationship with synapse size. Main analyses were performed in blocks from cingulate cortex and confirmed in blocks from the striatum of cases with dementia with Lewy bodies. A total of 1 318 700 single pre- or postsynaptic terminals were analysed. We found that phosphorylated α-synuclein is present exclusively in dementia with Lewy bodies cases, where it can be identified in the form of Lewy bodies, Lewy neurites and small aggregates (<0.16 µm3). Between 19% and 25% of phosphorylated α-synuclein deposits were found in presynaptic terminals mainly in the form of small aggregates. Synaptic terminals that co-localized with small aggregates of phosphorylated α-synuclein were significantly larger than those that did not. Finally, a gradient of phosphorylated α-synuclein aggregation in synapses (pre > pre + post > postsynaptic) was observed. These results indicate that phosphorylated α-synuclein is found at the presynaptic terminals of dementia with Lewy bodies cases mainly in the form of small phosphorylated α-synuclein aggregates that are associated with changes in synaptic morphology. Overall, our data support the notion that pathological phosphorylated α-synuclein may disrupt the structure and function of the synapse in dementia with Lewy bodies.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  array tomography; dementia with Lewy bodies; human tissue; p-α-synuclein; synapses

Mesh:

Substances:

Year:  2017        PMID: 29177427      PMCID: PMC5841145          DOI: 10.1093/brain/awx275

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  64 in total

1.  A pyramid approach to subpixel registration based on intensity.

Authors:  P Thévenaz; U E Ruttimann; M Unser
Journal:  IEEE Trans Image Process       Date:  1998       Impact factor: 10.856

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

3.  STED imaging performance estimation by means of Fourier transform analysis.

Authors:  David Merino; Arrate Mallabiabarrena; Jordi Andilla; David Artigas; Timo Zimmermann; Pablo Loza-Alvarez
Journal:  Biomed Opt Express       Date:  2017-04-17       Impact factor: 3.732

4.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.

Authors:  Robert M Koffie; Tadafumi Hashimoto; Hwan-Ching Tai; Kevin R Kay; Alberto Serrano-Pozo; Daniel Joyner; Steven Hou; Katherine J Kopeikina; Matthew P Frosch; Virginia M Lee; David M Holtzman; Bradley T Hyman; Tara L Spires-Jones
Journal:  Brain       Date:  2012-05-26       Impact factor: 13.501

5.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

6.  TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity.

Authors:  Mickael Decressac; Bengt Mattsson; Pia Weikop; Martin Lundblad; Johan Jakobsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

7.  Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease.

Authors:  K Wakabayashi; W G Honer; E Masliah
Journal:  Brain Res       Date:  1994-12-19       Impact factor: 3.252

8.  Synapse loss in the temporal lobe in Alzheimer's disease.

Authors:  S W Scheff; D A Price
Journal:  Ann Neurol       Date:  1993-02       Impact factor: 10.422

9.  Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.

Authors:  Rosemary J Jackson; Nikita Rudinskiy; Abigail G Herrmann; Shaun Croft; JeeSoo Monica Kim; Veselina Petrova; Juan Jose Ramos-Rodriguez; Rose Pitstick; Susanne Wegmann; Monica Garcia-Alloza; George A Carlson; Bradley T Hyman; Tara L Spires-Jones
Journal:  Eur J Neurosci       Date:  2016-11-12       Impact factor: 3.386

10.  Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia.

Authors:  Erika Bereczki; Paul T Francis; David Howlett; Joana B Pereira; Kina Höglund; Anna Bogstedt; Angel Cedazo-Minguez; Jean-Ha Baek; Tibor Hortobágyi; Johannes Attems; Clive Ballard; Dag Aarsland
Journal:  Alzheimers Dement       Date:  2016-05-22       Impact factor: 21.566

View more
  34 in total

1.  Brains for Dementia Research: The Importance of Cohorts in Brain Banking.

Authors:  Paul T Francis; Gillian M Hayes; Helen Costello; David R Whitfield
Journal:  Neurosci Bull       Date:  2019-01-02       Impact factor: 5.203

Review 2.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

3.  Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.

Authors:  David Coughlin; Sharon X Xie; Mendy Liang; Andrew Williams; Claire Peterson; Daniel Weintraub; Corey T McMillan; David A Wolk; Rizwan S Akhtar; Howard I Hurtig; H Branch Coslett; Roy H Hamilton; Andrew D Siderowf; John E Duda; Katya Rascovsky; Edward B Lee; Virginia M-Y Lee; Murray Grossman; John Q Trojanowski; David J Irwin
Journal:  Ann Neurol       Date:  2019-01-07       Impact factor: 10.422

Review 4.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

5.  Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype.

Authors:  Marina Buciuc; Jennifer L Whitwell; Koji Kasanuki; Jonathan Graff-Radford; Mary M Machulda; Joseph R Duffy; Edythe A Strand; Val J Lowe; Neill R Graff-Radford; Beth K Rush; Malgorzata B Franczak; Margaret E Flanagan; Matthew C Baker; Rosa Rademakers; Owen A Ross; Bernardino F Ghetti; Joseph E Parisi; Aditya Raghunathan; R Ross Reichard; Eileen H Bigio; Dennis W Dickson; Keith A Josephs
Journal:  Ann Neurol       Date:  2020-12-17       Impact factor: 10.422

6.  Immunotherapies Targeting α-Synuclein in Parkinson Disease.

Authors:  Fariha Jamal
Journal:  Fed Pract       Date:  2020-08

7.  Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Authors:  Alberto Lleó; Raúl Núñez-Llaves; Daniel Alcolea; Cristina Chiva; Daniel Balateu-Paños; Martí Colom-Cadena; Gemma Gomez-Giro; Laia Muñoz; Marta Querol-Vilaseca; Jordi Pegueroles; Lorena Rami; Albert Lladó; José L Molinuevo; Mikel Tainta; Jordi Clarimón; Tara Spires-Jones; Rafael Blesa; Juan Fortea; Pablo Martínez-Lage; Raquel Sánchez-Valle; Eduard Sabidó; Àlex Bayés; Olivia Belbin
Journal:  Mol Cell Proteomics       Date:  2019-01-03       Impact factor: 5.911

Review 8.  Dementia-related psychosis and the potential role for pimavanserin.

Authors:  Jeffery L Cummings; D P Devanand; Stephen M Stahl
Journal:  CNS Spectr       Date:  2020-08-19       Impact factor: 3.790

9.  Presynaptic accumulation of α-synuclein causes synaptopathy and progressive neurodegeneration in Drosophila.

Authors:  Jessika C Bridi; Erika Bereczki; Saffron K Smith; Gonçalo M Poças; Benjamin Kottler; Pedro M Domingos; Christopher J Elliott; Dag Aarsland; Frank Hirth
Journal:  Brain Commun       Date:  2021-03-22

10.  Templated α-Synuclein Inclusion Formation Is Independent of Endogenous Tau.

Authors:  Lindsay E Stoyka; Casey L Mahoney; Drake R Thrasher; Drèson L Russell; Anna K Cook; Anner T Harris; Ashwin Narayanan; Tiara P Janado; David G Standaert; Erik D Roberson; Laura A Volpicelli-Daley
Journal:  eNeuro       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.